NEW RAY MED-NEW (06108) Reports Interim Results with Net Loss of HK$7.454 Million, Widening 82.3% Year-on-Year

Stock News08-27

NEW RAY MED-NEW (06108) announced its interim results for 2025, reporting revenue of HK$44.701 million, representing a year-on-year increase of 167.4%. The company recorded a net loss of HK$7.454 million, which widened by 82.3% compared to the same period last year. Basic loss per share was HK$0.45 cents.

The increase in revenue during the period was attributed to the group's launch of new products in China starting from the second half of 2024. However, this growth was partially offset by declining demand for these products during the period, which was caused by the continued adverse impact from the further strengthening of antimicrobial stewardship policies across multiple regions in mainland China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment